[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530145":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":17,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":17,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":44,"whyStopped":17,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"APG-2575","EXPERIMENTAL","Dose escalation",[13],"Drug: APG-2575",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Other: Placebo",[21,25],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":17},"DRUG","Take orally once daily (QD) for 12 weeks.",[9],{"type":26,"name":15,"description":23,"armGroupLabels":27,"otherNames":17},"OTHER",[15],[29],{"name":30,"affiliation":31,"role":32},"Sheng Chen, Ph.D","Renji Hospital Shanghai Jiaotong University School of Medical","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":17,"email":38},"Yifan Zhai","CONTACT","240-505-6608","Yzhai@ascentage.com",{"name":40,"role":36,"phone":17,"phoneExt":17,"email":41},"Xiaofeng Han","Xiaofeng.Han@ascentage.com",[43],{"facility":31,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Shanghai","Shanghai Municipality","200127","China","CN",{"type":51,"coordinates":52},"Point",[53,54],121.45806,31.22222,{"lat":54,"lon":53},[57,60],{"name":30,"role":36,"phone":58,"phoneExt":17,"email":59},"13917556052","13917556052@139.com",{"name":61,"role":32,"phone":17,"phoneExt":17,"email":17},"Sheng Chen, Ph.D.",{"type":63,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR",[65],{"name":66,"class":6},"Suzhou Yasheng Pharmaceutical Co., Ltd.","100530145","phase-1-a-study-of-apg-2575-in-patients-with-mild-to-moderate-systemic-lupus-erythematosus-100530145",false,"NCT06182969","A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","A Randomized, Double-blind, Placebo-controlled Phase I\u002FII Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","Inclusion Criteria:\n\n* 1\\. Diagnosis of systemic lupus erythematosus for at least 6 months.\n* 2\\. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.\n* 3\\. SLEDIA-2000 score: 4-12\n* 4.Other than systemic lupus erythematosus, subject should be in general good health.\n\nExclusion Criteria:\n\n* 1\\. Severe systemic lupus erythematosus.\n* 2\\. Significant autoimmune disease other than lupus.\n* 3\\. Significant, uncontrolled or unstable disease in any organ.","FEMALE","18 Years","65 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82,83],"PHASE1","PHASE2","To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).",[86],"SLE",[86,9],"2025-12-14",{"date":90,"type":91},"2025-12-16","ACTUAL",{"date":93,"type":91},"2024-08-09",{"date":95,"type":79},"2026-12",{"name":5,"class":6},1]